Breaking News, Collaborations & Alliances

Portola, Daiichi Expand Clinical Collaboration

Establishes Phase III agreements for Factor Xa inhibitors

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Portola Pharmaceuticals has entered a second clinical collaboration with Daiichi Sankyo to study andexanet alfa, Portola’s investigational Factor Xa inhibitor in Phase III studies with Daiichi’s Factor Xa inhibitor edoxaban.   Portola will receive an upfront payment and is eligible to receive additional development and regulatory milestones. Portola retains full commercial rights to andexanet alfa. Financial details were not disclosed.   The original alliance, dating back to June 201...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters